Eli Lilly and Company has announced its acquisition of Ajax Therapeutics, focusing on Ajax’s lead candidate, AJ1-11095, a first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical trials. This investigational drug aims to offer deeper and more durable disease control for patients with myelofibrosis and polycythemia vera, particularly those who have previously been treated with Type I JAK2 inhibitors. With proof-of-concept data expected to be presented in late 2026, AJ1-11095 represents a significant advancement in the treatment landscape for myeloproliferative neoplasms (MPNs).

The significance of AJ1-11095 lies in its unique binding mechanism to JAK2, which differs from existing therapies that target the Type I conformation. Current JAK2 inhibitors often lead to treatment discontinuation due to a lack of sustained efficacy or loss of response. AJ1-11095 is designed to overcome these limitations, potentially providing a novel therapeutic option for patients who develop resistance to Type I inhibitors. The Phase 1 trial, initiated in late 2024, is expected to refine dosing for subsequent clinical development, highlighting the drug’s promise in enhancing treatment durability and patient tolerability.

The acquisition underscores a strategic shift in the development of therapies for MPNs, emphasizing the need for more effective treatment options. This move not only accelerates AJ1-11095’s clinical progression but also positions Lilly to leverage its expertise in blood cancers to expedite the drug’s entry into registrational trials. Such advancements could significantly shorten drug development timelines and reshape the therapeutic landscape for patients with MPNs, ultimately addressing a critical unmet need in this patient population.

Source: investor.lilly.com